As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by the Food and Drug Administration (FDA).As a quirky feature of the U.S. market, not having a therapeutic interchangeability designation is considered an important impediment to physician and patient […]